

CV - ALAN KIMURA, MD, MPH

PERSONAL

BUSINESS ADDRESS:

Colorado Retina Associates

255 S Routt St, Lakewood, CO 80228
(Research Office Location)

MEDICAL LICENSE:

Colorado - 35446; Expiration Date 4/30/21

NPI:

1851343214

GCP TRAINING:

Expires 3/18/2021

COLORADO RETINA ASSOCIATES:

Since 1/2006

BOARD CERTIFICATION:

Diplomate, American Board of Ophthalmology since 1988
Diplomate, National Board of Medical Examiners since
1982

I. Personal Data

Citizenship Status: U.S.A.

II. Education

1978 B. S. (Biology), University of Michigan, Ann Arbor, MI

1982 M. D., Chicago Medical School, North Chicago, IL

III. Post-Graduate Education

07/82 - 06/83 Flexible Internship, Good Samaritan Medical Center, Phoenix, AZ

07/83 - 06/86 Ophthalmology Residency, University of Illinois Eye and Ear Infirmary, Chicago, IL

01/87 - 12/88 Vitreoretinal Fellowship, University of Iowa, Iowa City, IA

01/87 - 06/87 Ocular Vascular Fellowship, Sohan Singh Hayreh, M.D., PhD, University of Iowa, Iowa City, IA

01/89 - 03/89 Clinical Electrophysiology Fellowship, University of Illinois Eye and Ear Infirmary, Chicago, IL

11/08 - 5/13 Masters of Public Health, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. MPH degree awarded May, 2013.

IV. Academic Appointments

07/86 - 12/86 Clinical Assistant Professor, University of Illinois Eye and Ear Infirmary, Chicago, IL

04/89 - 06/94 Assistant Professor, Department of Ophthalmology, College of Medicine, The University of Iowa, Iowa City, IA

07/94 - 07/96 Associate Professor with Tenure, Department of Ophthalmology, College of Medicine, The University of Iowa, Iowa City, IA

09/96 - Present Clinical Associate Professor, Department of Ophthalmology, College of Medicine, University of Colorado Health Sciences Center, Denver, CO

V. Other Employment Pertaining to Current Professional Appointments

07/86 - 12/86 General ophthalmology practice with Paul K. Morimoto, M.D., S.C., Joliet, IL

09/96 - 08/99 Vitreoretinal ophthalmology practice with Kevin D. Brady, M.D., P.C., Denver, CO

09/99 - 12/07 Retinal Alliance, P.C., five-person, vitreoretinal, single subspecialty, referral practice.

01/08 - Present Colorado Retinal Associates, P.C., eleven-person, vitreoretinal, single subspecialty, referral practice (merger).

VI. Certification and Licensure

A. Certification:

1. National Board of Medical Examiners, Diplomate 1982, No. 260493
2. American Board of Ophthalmology, Diplomate 1988

B. Licensure:

1. Colorado, No. 35446, 1996 - Present

C. Hospital Staff Admitting Privileges

1. St. Joseph Hospital, 1835 Franklin Street, Denver, CO 80205
2. Porter Hospital, 2525 South Downing Street, Denver, CO 80210,
3. Lowry Surgery Center, 8101 E. Lowry Boulevard, Denver, CO 80230
4. Red Rocks Surgery Center, 400 Indiana, Golden, CO 80401

VII. Professional Affiliations

1996 Colorado Ophthalmologic Society

1995 Retina Society

1991 American Society of Retinal Surgeons

1989 International society for Clinical Electrophysiology of Vision

1988 Association for Research in Vision and Ophthalmology

1988 Illinois Association of Ophthalmology

1987 Iowa Eye Association

1986 U.S. World Eye Foundation

1983 American Academy of Ophthalmology

1983 Chicago Ophthalmological Society

VIII. Clinical Research Projects, FDA Trials

ForseeHome (EMMES)- Sub-investigator, Title: Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD using the ForseeHome Device
2011-2013

AREDS2 (EMMES)- Sub-investigator, Title: Age-Related Eye Disease Study 2 (AREDS2): A Multicenter, randomized trial of lutein, zeaxanthin and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in age-related macular degeneration

MD71 10852 (GSK)-Sub-investigator, Title: A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

Omega- OT-551-C04: Sub-Investigator, Title: A randomized, double-masked, dose-ranging, multicenter, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration.

FAME (Alimera)- Sub-Investigator, Title: A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day Fluocinolone Acetonide Intravitreal Inserts to Sham injection in Subjects with Diabetic Macular Edema
2007-2010

FAME (Alimera) Sub-Investigator, Protocol: C-01-1 1-008, Sub-Investigator, Title: An Open Label, Multicenter Extension Study of the Safety and Utility of the Ne Inserter of ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) and the Safety of ILUVIEN in Subjects Diabetic Macular Edema
2010-2012

TIME-2: Sub-Investigator, Title: Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema.

CATT (University of Pennsylvania)- Sub-Investigator, Title: Multi-centered randomized clinical trial to assess the relative safety and efficacy of two treatments for subfoveal Neovascular Age-Related Macular Degeneration (AMD).
2014-2015

DENALI (Novartis)-Sub-Investigator, Title: A 24 month Randomized, Double-Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin (Visudyne) Photodynamic Therapy Administered in Conjunction with Ranibizumab (Lucentis) versus Ranibizumab (Lucentis) Monotherapy in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
2007-2010

Posurdex (Allergan): Sub-Investigator, Title: A Phase 2, Multicenter, Masked, Randomized, Sham-Controlled 12-Month Trial (Plus a 12-Month Masked Extension) to Assess the Safety and Efficacy of a 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System as Adjunctive Therapy to Photodynamic Therapy with Verteporfin (PDT) in the Treatment of Patients with Age-Related Macular Degeneration (ARMD)

BRAVO (Genentech)-Sub-Investigator, FVF4 165g: A Phase II Multicenter, Randomized Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary 1 Branch Retinal Vein Occlusion
2008-2011

CRUISE (Genentech)-Sub-Investigator, FYF4166g: Title: A Phase III Multicenter, Randomized Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary 1 Central Retinal Vein Occlusion
2008-2011

HORIZON – FVF3426g: Sub-Investigator, Title: An Open Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMO) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have Completed a Genentech-sponsored Ranibizumab Study.

Novartis CRAD01A2203: Sub-Investigator, Title: A randomized, double-masked, parallel group study to assess the efficacy of oral Everolimus 5 mg once daily, either alone or added to Lucentis, in patients with neovascular age-related macular degeneration.

INSURE (Novartis) Sub-Investigator, Protocol: CAIN457C2302, Title: A 28 week Multicenter, Randomized, Double-Masked, Placebo-Controlled, dose-Ranging Phase III Study to Assess AIN457 versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults with Active, Non-Infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression.

VIEW (Regeneron), Protocol: YGTF-OD-0605, Sub-Investigator, Title: A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal YEGF Trap with Neovascular Age-Related Macular Degeneration

DNA Repository Sub Study in Association with Ranibizumab Study FBF4579g: (Genentech): Title: A Phase III, Double-Masked, Multicenter, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg of Ranibizumab administered monthly or on an as needed basis (prn) with a Safety Run-In of a Single Dose of 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.

2009-2011

RISE (Genentech): Protocol: FVF4168g, Sub-Investigator, Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus

HARBOR (Genentech): FVF4579G-A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2/0 mg Ranibizumab Administered Monthly or on an as-needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

2009-2012

SHORE (Genentech) : FVF4967G-A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion

2011-2012

SEATTLE (Acucela) Protocol: 4429-202, Investigator Title: A Phase 2b/3 multicenter, randomized, double-masked, dose ranging study comparing the efficacy and safety of emixustat HCL (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration.

2013-2016

BAM (GSK)- Principal Investigator, Title: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy,

Pharmokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
2012-2016

FOVISTA (Ophthotech): Protocol: OPH1003- Investigator, A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of FOVISTA™ (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration
2014-present

FORSIGHT (Forsight, Inc)- Investigator, A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404PDS in Chronic Noninfectious Uveitis
2014-2015

ORA (Aerpio Therapeutics) Investigator, Title: A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 months, as Monotherapy or Adjunctive to Ranibizumab, In Subjects with Diabetic Macular Edema
2014-2015

TOGA (University of Virginia) Investigator, A Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration
2014-present

ORBIT (Thrombogenics) Protocol: TG-MV-018, Sub-Investigator Title: Ocriplasmin Research to Better Inform
2014-present

EYEGUARD (XOMA) Sub-Investigator, Title: A Randomized, Double-Masked, Placebo Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
2012-2015

EYEGUARD (XOMA) Sub-Investigator, Title: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment
2012-2015

REVIEW: (Regeneron) Protocol: VGFT e-AMD-1124, Sub-Investigator, Title: Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-related Macular Degeneration.

SAKURA (Santen, Inc) Protocol: DE-109, Sub-Investigator, Title: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of The Posterior Segment of the Eye
2012-present

STOP (Genentech, University of Nebraska) Protocol number: ML28522, Sub-Investigator, Title: Study of the safety, tolerability and bioactivity of tocilizumab on patients with noninfectious uveitis
2012-present

OPTINA (Ampio Pharmaceuticals) Sub-Investigator, Title: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema
2013-2015

OCULOS (Ohr Pharmaceuticals) Protocol: OHR-002, Sub-Investigator, Title: A Phase 2 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
2012-2015

EMERGE (ICONIC): Protocol: IT-002, Investigator, Title: A Phase II, Randomized, Double-Masked, Multicenter, Active-Controlled Study Evaluating the Safety of Repeated Intravitreal injections of hL-con1 administered as monotherapy or in combination with ranibizumab compared to ranibizumab monotherapy.
2015-present

XCOVERY: (Tyrogenex) Protocol: X82-OPH-201, Sub-Investigator, Title: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea® monotherapy in Neovascular AMD
2015-present

SPECTRI (LAMPA) (Regeneron) Sub-Investigator, Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
2015-present

NEUROTECH: (Neurotech) Protocol: NT-503-3-AMD-001), Sub-Investigator, Title: A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea® for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
2015-present

LADDER (Genentech) Protocol: GX28228, Sub-Investigator, Title: Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
2015-present

VIDI (ASTELLAS): Protocol: 8232-CL-001, Sub-Investigator, Title: A Phase II, Double-Masked, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema
2015-present

HAWK (Alcon): Protocol RTH258-C001, Sub-Investigator, Title: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Afibercept in Subjects with Neovascular Age-Related Macular Degeneration

2015-present

CAPELLA (Regeneron) Protocol: R2176-3-AMD-1417, Sub-Investigator, Title: A Phase II, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176—3 in Patients with Neovascular Age-Related Macular Degeneration

2015-present

CEDAR (Allergan): Protocol: AGN-150998, Sub-Investigator, Title: A Multicenter, Double-Masked, Randomized 100-week, Parallel-Group, Active-Controlled Study to Evaluate the Safety and Efficacy of Abicipar in Treatment-Naïve patients with Neovascular AMD.

2015-present

VAPOR (Santen) Protocol: 35-002: Sub-Investigator, Title: A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect on Intravitreal Injections of DE-120 (a VEGF and PDGF Receptor Inhibitor) as Monotherapy and with a Single Eyelea® Injection in Subjects with Treatment-Naïve Exudative Age-Related Macular Degeneration.

2015-present

ALDEYRA (Aldeyra) Protocol: NS2-02, Sub-Investigator, Title: A Phase 2, Randomized, Investigator-Masked, Comparator Controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis

2015-present

AVENUE (Roche) Protocol: BP29647, Sub-Investigator, Title: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

2015-present

PROXIMA (Genentech) Protocol: GX29633, Investigator, Title: A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

2015-present

LHA510 (Alcon/Novartis) Protocol: LHA510-2201, Investigator, Title: A Randomized, Double-Masked, Vehicle-Controlled, Proof-of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet Age-Related Macular Degeneration.

2015-present

VISTA (Regeneron) Protocol: VGFT-OD-1009, Sub-Investigator, Title: A Double-Masked, Randomized, Active-Control, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Degeneration

2011-2015

AURA (Aura Biosciences) Protocol: AU-011-201, Sub-Investigator, Title: A Prospective, Randomized, Multi-Center, Masked Clinical Trial Designed to Evaluate Two Doses of Light-Activated AU-011 for the Treatment of Subjects with Small to Medium (1.5-4.0 mm thickness) Primary Uveal Melanoma

2016

UPCOMING 2016:

PANORAMA (Regeneron) Protocol: VGFT-E-1412
EXPOSURE (Genentech) Protocol: GX29455
EYEGATE (Eyegate) Protocol: EGP-437-006

Protocol No.: EOP1013 (Eyeteck DME)

A Phase 2/3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, In Parallel Groups, to Compare the Safety and Efficacy of Intravenous Injections of 0.3, 0.03 or 0.003 mg Pegaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 Years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula.

Protocol No.: PTK787 E2201 (Novartis PTK) Novartis Pharmaceuticals Trial Entitled: A Randomized, Double-Masked, Multi-Center, Phase I/II Study of the Safety of PTK 787 Administered in Conjunction with Photodynamic Therapy with Visudyne® to Patients with Predominantly Classic, Minimally Classic or Occult with no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

Protocol No.: MSI-1256F-209 (Genaera 209)

A Phase 2, Multi-Center, Randomized, Masked, Controlled, Study of MSI-1256F (Squalamine Lactate) for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.

Protocol No.: MSI1256F-301 (Genaera 301)

A Phase 3, Multi-Center, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.

Protocol No.: CBPD952E2202 (Novartis VERITAS)

A 24-Month, Randomized, Double-Masked, Sham-Controlled, Multi-Center, Phase IIIB Study Comparing Photodynamic Therapy with Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) versus Visudyne® plus Intravitreal Pegaptanib (Macugen®) in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

Allergan – AMD STUDY NUMBER AGN: 206207-014-01

A Phase 2, Multi-Center, Masked, Randomized, Sham-Controlled 12-Month Trial (Plus a 12-Month Masked Extension) to Assess the Safety and Efficacy of a 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System as Adjunctive Therapy to Photodynamic Therapy with Verteporfin (PDT) in the Treatment of Patients with Age-Related Macular Degeneration (ARMD).

Allergan - Anterior Segment Uveitis

STUDY NUMBER AGN: 206207-013-00

Allergan 206207-015-01: A 4-Week, Phase 3, Multi-Center, Masked, Randomized Trial (with a 22-Week masked Safety Extension) to Assess the Safety and Efficacy of a 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Anterior Segment in Patients with Anterior Uveitis.

Protocol FVF4165g: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion. Sponsor: Genentech.

Protocol FVF4166g: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion. Sponsor: Genentech.

Protocol: FVF4141s: VEGF and HTRA1 DNA polymorphisms in neovascular AMD pathogenesis and response to Lucentis. Sponsor: Genentech through the University of Utah.

IX. Former University of Iowa, Department of Ophthalmology, Teaching Activities (1987-1996)

- | | | |
|----|--|----------------|
| A. | Retina Clinic | 14 hours/week |
| B. | Ophthalmology morning rounds | 4-5 hours/week |
| C. | Ophthalmology monthly grand rounds | 6 hours/year |
| D. | Ophthalmology lecture to medical students | 3-6 hours/year |
| E. | Ophthalmology tours to alumni | 1-2 hours/year |
| F. | Vitreoretinal surgery and preop/post-op teaching | 10 hours/week |
| G. | Retinal fluorescein work rounds | 1 hour/week |
| H. | Supervise Electrophysiology Service in Department of Ophthalmology five days a week. | |
| I. | Teaching Activities (Other) | |
| 1. | Establish Community Ophthalmology - Supervise 3-4 residents in Iowa | |
| 2. | City Free Ophthalmology Clinic one Saturday each month | |

X. Current University of Colorado Health Science Center, Department of Ophthalmology, Teaching Activities (1996-Present)

- | | | |
|----|--|--------------|
| A. | Fluorescein Angiography & Imaging Teaching Lecture | 1 hour/month |
|----|--|--------------|

XI. Continuing Education

1. Clinical Conference Continuing Education for Nurses/Technicians September 11, 1992 - Lecture - Electrophysiology Testing: What and Why?
2. Clinical Conference Continuing education for Nurses/Technicians October 15, 1993 - Ocular Manifestations of Hypertension.
3. University of Iowa Hospitals and Clinics, Department of Internal Medicine Grand Rounds, September 1993 - Diabetes 2000.
4. University of Iowa, Internal Medicine Department - Modern Management of Diabetes Seminar - September 16 and October 14, 1994 - Lectures - Preventing Eye Complications and Management of Complications of Diabetes: The Eyes.
5. American Academy of Ophthalmology Meeting - November 2, 1994 - 1994 Vitreoretinopathy Review and Update.
6. American Academy of Ophthalmology Meeting - November 2, 1994 - FFA Indications and Interpretations Lecture - ASORN Meeting.
7. American Academy of Ophthalmology Meeting - November 1994 - Retinal Laser Application Laboratory - Use of the Slit Lamp Delivery System.
8. American Academy of Ophthalmology Meeting - November 1994 - Guidelines for Evaluation and Treatment of Choroidal Neovascularization in the Macular Photocoagulation Study.
9. American Academy of Ophthalmology Meeting - November 1994 - Binocular Indirect Laser-Retinal Laser Application Laboratory.

10. University of Minnesota, Department of Ophthalmology, Grand Rounds - January 13 - 14, 1995 - Introduction to clinical electrophysiology of inherited diseases.
11. Clinical Conference Continuing Education for Nurses/Technicians - February 3, 1995 - Lecture - FFA Indications and Interpretations.
12. University of Iowa, Internal Medicine Department - Modern Management of Diabetes Seminar, April 7 and 14, 1995 - Lectures - Preventing Eye Complications and Management of Complications of Diabetes; The Eyes.
13. Retina Society, Santa Fe, New Mexico, September 6-10, 1995
14. American Board of Ophthalmology - Oral Examination, Associate Examiner, St. Louis, MO, October 13-15, 1995
15. University of Iowa, Internal Medicine Department - Modern Management of Diabetes Seminar, October 20, 1995 - Lectures - Preventing Eye Complications and Management of Complications of Diabetes; The Eyes.
16. American Academy of Ophthalmology Meeting - November 1995 - Guidelines for Evaluation and Treatment of Choroidal Neovascularization in the Macular Photocoagulation Study.
17. University of Iowa, Internal Medicine Department - Modern Management of Diabetes Seminar, March 1, 1996 - Lectures - Preventing Eye Complications and Management of Complications of Diabetes; The Eyes.
18. University of Iowa, Department of Ophthalmology Clinical Conference - Co-Host - How to Read a Fluorescein Angiogram, Guest speaker - Neil Bressler, M.D., April 12, 1996
19. Eighth Midwest Ocular Angiography Conference, Chateau Lake Louise, Lake Louise, Canada, July 31-August 3, 1996, presenter
20. American Academy of Ophthalmology Meeting - November 1996 - Guidelines for Evaluation and Treatment of Choroidal Neovascularization in the Macular Photocoagulation Study.
21. American Academy of Ophthalmology Meeting - November 1996 - Inherited Vitreoretinopathies Update.
22. American Academy of Ophthalmology Meeting - November 1997 - Guidelines for Evaluation and Treatment of Choroidal Neovascularization in the Macular Photocoagulation Study.
23. American Academy of Ophthalmology Meeting - November 1997 - Inherited Vitreoretinopathies Update.
24. American Board of Ophthalmology - Oral Examination, Associate Examiner, San Francisco, June 5-7, 1998.
25. Tenth Midwest Ocular Angiography Conference, Sundance Resort, Sundance, Utah, July 25-28, 1998, presenter
26. American Academy of Ophthalmology Meeting - November 1998 - Guidelines for Evaluation and Treatment of Choroidal Neovascularization in the Macular Photocoagulation Study.
27. American Academy of Ophthalmology Meeting - November 1998 - Inherited Vitreoretinopathies Update, lecturer.
28. Eleventh Midwest Ocular Angiography Conference, Chateau Whistler, Whistler, BC, Canada, August 4-7, 1999, presenter
29. Ocular Inflammation Society, Istanbul, Turkey, June 17-23, 2000
30. Ocular Inflammation Society, Reykjavik, Iceland, July 17-21, 2000
31. American Academy of Ophthalmology, Dallas, Texas, October 22-25, 2000; Subspecialty Day-Retina & Annual Meeting
32. Wilderness Medicine Symposium, Snowmass Village, Snowmass, Colorado, August 12-17, 2001
33. American Academy of Ophthalmology, New Orleans, Louisiana, November 9-13, 2001; Subspecialty Day-Retina & Annual Meeting
34. Colorado Society of Eye Physicians and Surgeons, 31st Annual Mid-Winter Meeting, Copper Mountain, Colorado, February 1-3, 2002
35. Fourteenth Midwest Ocular Angiography Conference, July 2002, presenter
36. Retina Society, San Francisco, California, September 2002
37. American Board of Ophthalmology, Associate Examiner, Oral Board Examination, San Francisco, California, November 8-10, 2002

38. The Metabolic Syndrome: Rocky Mountain Symposium: The Latest Diagnostic & Therapeutic Approaches, Adams Mark Hotel, Denver, Colorado, April 2003
39. Fifteenth Midwest Ocular Angiography Conference, Fairmont Jasper Park Lodge, Jasper, Alberta, Canada, August 6-9, 2003, presenter
40. Retina Society, Chicago, Illinois, September 18-21, 2003
41. American Academy of Ophthalmology, Anaheim, California, November 14-18, 2003; Subspecialty Day-Retina & Annual Meeting
42. American Board of Ophthalmology, Associate Examiner, Oral Board Examination, San Francisco, California, November 12-14, 2004
43. Foundation Fighting Blindness: Science & Technology Conference on Retinal Degenerative Diseases, Lecturer on "Anatomy & Physiology of the Eye and Retina: Photoreceptors and Retinal Degenerative Diseases"; "Inherited Retinal Disease and Retinal Testing," Cable Center, Denver, Colorado, April 14, 2005
44. AMD Management: PDT & Combination Therapies, The Ritz-Carlton, South Beach, Florida, June 3-5, 2005
45. Seventeenth Midwest Ocular Angiography Conference, Whistler, British Columbia, Canada, August 3-6, 2005, presenter.
46. American Academy of Ophthalmology, Chicago, Illinois, Subspecialty Day-Retina, October 14-15, 2005 & Annual Meeting October 15, 2005; Ocular Imaging Conference, October 15, 2005, presenter.
47. Miami Angiogenesis 2006, Mandarin Oriental Hotel, Miami, Florida, February 3-4, 2006.
48. Genentech Retina Experts Advisory Board Meeting, Vail Mountain Marriott, Vail, Colorado, March, 18, 2006
49. American Board of Ophthalmology, Oral Board Examination, Associate Examiner, San Francisco, California, June 9-11, 2006
50. Midwest Ocular Angiography Course, Girdwood, Alaska, August 2-5, 2006, presenter.
51. Foundation Fighting Blindness Denver Vision Walk Kickoff Luncheon, Littleton, Colorado, August 21, 2006
52. Genentech Advisory Board, Half-Moon Bay, California, August 25, 2006
53. Macula - 2006, Hotel Inter-Continental, Paris, France, September 6, 2006
54. American Society of Retina Specialists, Palais d' Festival, Cannes, France, September 9-13, 2006
55. The Foundation Fighting Blindness Mile High Chapter Meeting, Lecturer on "Retinal Degenerative Diseases—Breakthroughs Update," Denver, Colorado, October 21, 2006
56. Holy Cross Lutheran Church, Lecturer on "Macular Degeneration: Breakthroughs in Therapy," Wheat Ridge, Colorado, October 22, 2006
57. American Academy of Ophthalmology, Retina 2006: Emerging New Concepts, Las Vegas, Nevada, November 10-11, 2006
58. Alcon Focus Group, Venetian Resort Hotel Casino, Las Vegas, Nevada, November 11, 2006
59. Genentech Thought Leader dinner, Canaletto, Venetian Resort Hotel Casino, Las Vegas, Nevada, November 10, 2006
60. QLT Combination Therapy Registry dinner, Mirage Resort Hotel Casino, Las Vegas, Nevada, November 11, 2006
61. Ophthalmic Imaging Conference, Renaissance Hotel, Las Vegas, Nevada, November 12, 2006
62. Foundation Fighting Blindness "Day of Science," Omni Orlando Championsgate Hotel, Orlando, Florida, January 25-27, 2007
63. Foundation Fighting Blindness Medical Advisory Team Dinner Host, Elway's Restaurant, Denver, Colorado, February 13, 2007
64. Miami Angiogenesis 2007, Ritz-Carlton Hotel, Key Biscayne, Florida, February 22-24, 2007
65. Genentech Lucentis Retina Experts Meeting, St. Regis Hotel, San Francisco, California, March 16-17, 2007
66. Association for Research in Vision and Ophthalmology (ARVO) 2007: The Aging Eye, Broward County Convention Center, Fort Lauderdale, Florida, May 5-10, 2007
67. Metabolic Syndrome: Rocky Mountain Symposium, Renaissance Denver Hotel, Denver, Colorado, May 11, 2007

68. Foundation Fighting Blindness Mile-High Chapter: ARVO 2007 Update, Daniels Building, Denver, Colorado, May 12, 2007
69. 11th Annual Ophthalmology Research Day, The Rocky Mountain Lions Eye Institute, University of Colorado School of Medicine, Fitzsimmons campus, Presented "AMD: From 'Senility' to Polymorphisms," Denver, Colorado, June 15, 2007
70. ARVO Summer Eye Research Conference: Preventing Vision Loss in Diabetic Retinopathy, Crowne Plaza Hotel, Warwick, Rhode Island, July 15-18, 2007
71. KMGH Channel 7 News, live interview on Age-Related Macular Degeneration, Porter Adventist Hospital, Denver, Colorado, July 24, 2007
72. Foundation Fighting Blindness Kickoff Luncheon, Presenting "Update on Scientific Advances in Treating Blinding Disorders," Hudson Gardens, Littleton, Colorado, August 8, 2007
73. Presenting "AMD in the 21st Century," Omni Interlocken Hotel, Flatirons Crossing, Westminster, Colorado, August 16, 2007
74. Association for Research in Vision, Summer Eye Research Conference, Portola Plaza Hotel, Monterey, California, August 22-25, 2007
75. ARVO SERC Genetics and Eye Diseases, Portola Plaza Hotel, Monterey, California, August 22-25, 2007
76. "Mini-Symposium on the Management of AMD: Neovascular Age-Related Macular Degeneration," presented by the Johns Hopkins University School of Medicine, Denver Art Museum, Denver, Colorado, September 6, 2007
77. "Advanced Vitreoretinal Techniques and Technology: Chicago Conference," Marriott Hotel Magnificent Mile, Chicago, Illinois, September 8-9, 2007
78. The Foundation Fighting Blindness, VisionWalk-Denver-Year 2, Hudson Gardens, Littleton, Colorado, Walk Chair, Alan Kimura, M.D., September 29, 2007
79. Vision Seminar Series-Denver. "AMD in the 21st Century" presented by Alan Kimura, M.D., University of Denver, Davis Auditorium in Sturm Hall, Denver, Colorado, Sponsored by The Foundation Fighting Blindness, October 13, 2007
80. First Annual DIRECT Dry AMD Meeting, sponsored by The Duke University School of Medicine and Focus-ed, The Washington Duke Inn & Golf Club, Durham, North Carolina, October 25-27, 2007
81. Retina 2008, Hilton Waikoloa Village, Hawaii's Big Island, January 20-25, 2008
82. Angiogenesis, Degeneration, and Exudation 2008, The Ritz-Carlton, Key Biscayne, Florida, February 22-23, 2008
83. Foundation Fighting Blindness Day of Science, Omni San Diego, San Diego, California, February 28-March 1, 2008
84. "Ophthalmology: Diagnoses and Procedures," American Association of Professional coders, Veterans Administration Hospital, Denver, Colorado, March 11, 2008
85. "Age-Related Macular Degeneration and Inherited Retinal Diseases Update 2008," Vision Matters, 2008 Conference, Fort Collins, Colorado
86. "Diabetic Retinopathy: Seeing Beyond Sugar," Rocky Mountain Association of Diabetes Educators Education Conference, PPA Event Center, Denver, Colorado, April 11, 2008
87. OSI Clinical Roundtable, Swissotel, Chicago, Illinois, April 12, 2008
88. Rocky Mountain Metabolic Syndrome Symposium 2008, Renaissance Denver Hotel, Denver, Colorado, May 7, 2008
89. Presented "Gene Therapy and Leber's Congenital Amaurosis," Foundation Fighting Blindness, Swing for Sight Tournament, Omni Interlocken Hotel, Westminster, Colorado, June 16, 2008
90. 2008 Summer Eye Research Conference, Ocular Autoimmunity and Inflammation, Association for Research in Vision and Ophthalmology, Portola Plaza Hotel, Monterey, California, July 31- August 2, 2008
91. Presented "Age-Related Macular Degeneration: The 21st Century," at Capabilities, Westminster, Colorado, September 23, 2008
92. Retina Society, Scottsdale, Arizona, The Fairmont Hotel, Scottsdale, Arizona, September 25-26, 2008

93. Technology Update for Retinal Specialists, Foundation Fighting Blindness, Denver, Colorado, February 12, 2009
94. Presented "A Public Health and Medical Perspective of Age-Related Macular Degeneration," Foundation Fighting Blindness, St. Joseph's Hospital Russell Pavilion, Denver, Colorado, February, 14, 2009
95. "Day of Science," Foundation Fighting Blindness, Omni Hotel Championsgate, Orlando, Florida, February 28, 2009
96. American Academy of Ophthalmology Mid-Year Forum and Congressional Advocacy Day, lobbying Congresswoman Dianna DeGette, Senator William Bennett, and Senator Mark Udall, Capitol Hilton, Washington, D.C., April 22-24, 2009
97. Twelfth Annual Vision Research Conference: Mechanisms of Macular Degeneration, Elsevier. Ft. Lauderdale/Broward County Convention Center, Fort Lauderdale, Florida, April 30-May 1, 2009
98. ARVO (Association for Research in Vision and Ophthalmology) 2009 Annual Meeting, "Reducing Disparities in Eye Disease and Treatment, Fort Lauderdale/Broward County Convention Center, Fort Lauderdale, Florida, April 30-May 6, 2009
- 98a. American Board of Ophthalmology, Oral Board Examination, Associate Examiner, Swissotel, Chicago, Illinois, June 5-7, 2009
99. Midwest Ocular Angiography Conference, Hilton Hotel, Reykjavik, Iceland, July 22-25, 2009, presenter
100. Retina Congress, Sheraton Hotel, New York City, September 30-October 2, 2009
101. American Academy of Ophthalmology, Annual Meeting, Moscone Center, San Francisco, California, October 24-26, 2009
102. Scientific Poster 743 "Persistent Elevation of Intraocular Pressure Associated with Intravitreal Bevacizumab Treatment" Naresh Mandava, David Ammar, Alan Kimura, Malik Kahook. Retina Congress 2009 New York: A Combined Meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society, September 30-October 4, 2009
103. American Academy of Ophthalmology Mid-Year Forum & Congressional Advocacy Day, Capital Hilton, Washington, D.C., April 21-23, 2010
104. Biobootcamp, Holland & Hart, LLC, Denver, Colorado, April 29-30, 2010
105. Association for Research in Vision and Ophthalmology (ARVO), Broward County Convention Center, Fort Lauderdale, Florida, May 1-5, 2010
106. ARVO, "Comparative Effectiveness Research" course by Kevin Frick, PhD, Broward County Convention Center, Fort Lauderdale, Florida, May 1, 2010
107. Foundation Fighting Blindness, Denver Mile High Chapter, Lecture: "ARVO 2010 Update" presentation, Parkdale Senior Center, Denver, Colorado, May 8, 2010
108. American Academy of Ophthalmology OPHTHPAC & Congressional Advocacy Committee Retreat, Seelbach Hilton, Louisville, Kentucky, May 14-16, 2010
109. Human Genome Organization meeting, Le Corum, Montpellier, France, May 17-21, 2010
- 109a. Ophthalmic Photographers Society meeting, Crowne Plaza Hotel, Denver, Colorado. Presented lecture entitled, "Paradigm Shifts: Awareness & Action," June 19, 2010
110. Midwest Ocular Angiography Course, 22nd Annual, Presented Unilateral Cancer Associated Retinopathy, Fairmont Jasper Lake Lodge, Jasper Alberta, Canada, August 4-7, 2010, presenter
111. American Society of Retina Specialists, Vancouver, Canada, August 28-September 1, 2010
112. Retina Society Annual Meeting, Fairmont Hotel, San Francisco, California, September 18-25, 2010.
113. American Academy of Ophthalmology Annual Meeting, McCormick Place Convention Center, Chicago, Illinois, October 15-17, 2010; Ocular Imaging Conference, presenter; Ophthalmic Photographers Society, lecture: "Paradigm Shifts: Awareness & Action"
114. American Society of Human Genetics Annual Meeting, Moscone Center, San Francisco, California, November 1-5, 2010
115. Health One Ambulatory Surgery Centers, Physician Retreat: Challenges with ACA Implementation, Cheyenne Mountain, Colorado, January 28-20, 2011.

116. Mile-High Masters of Retina, Hyatt, Denver, Colorado, February 11, 2011; lecturer
117. American Academy of Ophthalmology Congressional Advocacy Day & Mid-Year Forum, Washington, DC, April 6-9, 2011; OPHTHPAC Committee; AAO Council Regional Meeting presenter
118. Association for Research in Vision & Ophthalmology Annual Meeting, Broward County Convention Center, Fort Lauderdale, Florida, April 30-May 3, 2011
119. Midwest Ocular Angiography Conference Annual Meeting, Four Seasons, Papagayo, Costa Rica, August 4-6, 2011, presenter
120. Cost-Containment Summit, Grand Hyatt, Washington, DC, October 26-28, 2011
121. Center for Improving Value in Health Care, Physician Payment Workgroup meeting, Denver, Colorado, December 14, 2011
122. American Academy of Ophthalmology Leadership Development Program Course, San Francisco, California, January 13-15, 2012
123. American Academy of Ophthalmology OPHTHPAC Committee Retreat, Phoenix, Arizona, March 30-April 1, 2012
124. American Academy of Ophthalmology Congressional Advocacy Day & Mid-Year Forum, Washington, DC, April 24-28, 2012; OPHTHPAC Committee; AAO Council Regional Meeting presenter
125. Colorado Medical Society, Spring Meeting, Sonnenalp, Vail, Colorado, May 4-6, 2012
126. American Board of Ophthalmology, Oral Board Examination, Associate Examiner, May 1-3, 2012
127. Ocular Imaging Conference, Summer Meeting, Vail, Colorado, June 23-26, 2012, presenter
128. Midwest Ocular Angiography Conference Annual Meeting, Quebec, Canada, July 29-August 4, 2012, presenter
129. American Society of Retina Specialists Annual Meeting, Las Vegas, Nevada, August 24-28, 2012.
130. Colorado Medical Society Annual Meeting, Keystone, Colorado, September 7-8, 2012
131. American Society of Human Genetics Annual Meeting, Moscone Center, San Francisco, California, November 6-8, 2012
132. American Academy of Ophthalmology Annual Meeting, McCormick Place Convention Center, Chicago, Illinois, November 9-12, 2012; OPHTHPAC Committee; AAO Council Regional Meeting presenter; Leadership Development Program
133. Mile-High Masters of Retina, Hyatt, Denver, Colorado, February 10, 2013, Lecture: "Diabetic Retinopathy: Economics, Politics, Culture"
134. American Academy of Ophthalmology Congressional Advocacy & Mid-Year Forum, Washington, DC, April 10-13, 2013; Presenter: "Electronic Health Records Improvement Act"; OPHTHPAC Committee
135. Human Genome Organization Annual Meeting, Singapore, April 14-18, 2013
136. Colorado Medical Society Spring Meeting, Sonnenalp, May 4-5, 2013
137. International Society for Pharmacoeconomics Outcomes Research meeting, Sheraton
138. Institute for Health Technology Transformation meeting, Hyatt Denver Tech Center, Denver, Colorado, July 24-25, 2013
139. Colorado Health Foundation Symposium, webinar August 7-9, 2013
140. American Society of Retina Specialists Annual Meeting, Toronto, Canada, August 23-27, 2013; meeting reporter and video interviewer
141. International Society for Pharmacoeconomics Outcomes Research, Hilton Hotel, Buenos Aires, Argentina, September 12-14, 2013
142. Colorado Medical Society, Annual Meeting, Sonnenalp, Vail, Colorado, September 21-22 2014.
143. American Board of Ophthalmology, Oral Board Exam, Associate Examiner, Swissotel, Chicago, Illinois, October 25-27, 2013.
144. American Academy of Ophthalmology Annual Meeting, New Orleans Convention Center, New Orleans, LA, November 14-18, 2013; Subspecialty Day, Retina meeting; Global Alliances meeting with Philippine Academy of Ophthalmology, post-Typhoon Haiyan relief; OPHTHPAC Committee meeting; AAO Council Regional Meeting presenter

145. Johns Hopkins Bloomberg School of Public Health, Winter Institutes, Post-MPH Degree, Course: "Human-Rights Based Approach & Public Health", Baltimore, Maryland, January 6 - 10, 2014.
146. International Ocular Inflammation Society Annual Meeting, Valencia, Spain, February 27 - March 2, 2014.
147. Foundation Fighting Blindness Visions Meeting, St. Joseph's Hospital, Lecture: "Age-Related Macular Degeneration: Current Treatments and Research", March 8, 2014
148. World Ophthalmology Congress, Tokyo International Forum, Tokyo, Japan. March 29-April 4, 2014
149. American Academy of Ophthalmology Congressional Advocacy Day & Mid-Year Forum, Washington, DC, Presenter at Mid-Year Forum: "Electronic Health Records Improvement Act", April 9, 2014.; health policy liaison staff meetings of Senator Bennet, Senator Udall, Congresswoman DeGette, April 10 2014; Council Regional Meeting, presenter "Colorado Eye Physicians and Surgeons Annual Report", April 11, 2014
150. Texas Ophthalmologic Association Annual Meeting, Fort Worth, Texas. Lecturer: "Genetics in Ophthalmology", May 1-3, 2014
151. Colorado Medical Society, Spring Meeting, Sonnenalp, Vail, Colorado, May 17, 2014

- xxx Foundation Fighting Blindness VISIONS Seminar. 1st Live Nationally Broadcast Lecturer: "Age-Related Macular Degeneration", Omni Interlocken Hotel, June 19, 2014.
- xxx Ocular Imaging Conference, Presenter: "Ophthalmic Genetics Update", Four Seasons Hotel, Vail, Colorado, June 26, 2014.

- 15x U.S. Retina, Invited Lecturer: "Diffusion of Innovations Theory, Or 'How Do Ideas Spread'?", Pensacola, Florida, July 25-27, 2014.
- Xxx 1st ASEAN Ophthalmology Societies Congress, Invited Lecturer (3 lectures): "Electronic Health Records: Economics, Politics, and Culture", Bangkok, Thailand, August 8-10, 2014.
152. American Society of Retina Specialists Annual Meeting, San Diego, California, August 8-11, 2014
153. Boulder Valley IPA Meeting, Keynote Lecturer: "Practice Efficiency In A Time Of Compliance Mandates", Omni Interlocken Hotel, Broomfield, Colorado, September 13, 2014
154. Colorado Medical Society Annual Meeting, Vail, Colorado. Panelist & Presenter: "Medicaid Specialty Physician Access Issues", September 20, 2014
155. US News & World Report: Hospital of Tomorrow conference, Washington Hilton, Washington, D.C, October 6-8, 2014.
156. American Academy of Ophthalmology Retina Subspecialty Day, Presenter: "Advocating For Your Patients And Your Profession" on behalf of AAO OPHTHPAC, McCormick Place, Chicago, Illinois, October 17, 2014
157. American Association of Eye and Ear Centers of Excellence Annual Meeting. Invited Lecturer: "Saving Money and Increasing Physician Satisfaction: The Success of Medical Scribes in Ophthalmology" W Hotel, Chicago, Illinois, October 20, 2014.
158. Bridges To Care Graduation Ceremony, Jeffrey Brenner, MD, Metro Care Providers Network, Aurora, Colorado, January 2015.
158. U.S. Retina, Board of Directors meeting, Camelback Inn, Phoenix, AZ, February 6-8, 2015.
159. Institute for Healthcare Improvement, 16th Annual International Summit on Improving Patient Care in the Office Practice & the Community, Gaylord Texan Resort & Convention Center, Dallas, Texas, March 15-17, 2015

XI. Other Professional Activities

Reviewer, Archives of Ophthalmology

1988 - 1996

- Reviewer, American Journal of Ophthalmology 1989 - 1996
- Reviewer, Ophthalmology 1992 - 1996
- Reviewer, Documenta Ophthalmologica 1993 - 1996
- Associate Examiner for Oral Boards, American Board of Ophthalmology
1993 - 2014 Present
- Reviewer, Retina 1998 - 2000
- Medical Advisory Committee, Lowry Surgery Center, Health One, Denver, Colorado
2005 - 2014, Present
- Operating Room Committee, Lowry Surgery Center, Health One, Denver, Colorado
2005 - 2014, Present
- Medical Chair, Denver Vision Walk, Foundation Fighting Blindness 2006 - 2013, Present; Denver's
Vision Walk has raised over \$900,000 to date (2006-2013)

Foundation Fighting Blindness Denver Vision Walk Kick-Off Luncheon, August 21, 2006,
Hudson Gardens, Denver, Colorado, lecturer

Foundation Fighting Blindness Denver Vision 5K Walk, Denver Medical Chair, September 30,
2006, Hudson Gardens, Denver, Colorado. Raised over \$105,000.

Foundation Fighting Blindness Denver Vision Walk, Denver Medical Chair and Walk Chair,
September 29, 2007, Hudson Gardens, Denver, Colorado. Raised \$97,000.

Foundation Fighting Blindness Denver Vision Walk, Denver Medical Chair, September 27,
2008, Cheeseman Park, Denver, Colorado. Raised over \$113,000.

Board of Managers, Red Rocks Surgery Center, Health One, Golden, Colorado, 2012 - 2014

Colorado Coalition for the Medically Underserved Annual Meeting, Denver, Colorado, May 20, 2014

Mile-High Health Alliance, asked to serve and represent specialty physicians for Medicaid access
issues, 2014

XII. Collegiate, University, University Hospitals, State and National Committees

- 1990 University of Iowa Hospitals: Department of Ophthalmology Quality Assurance Committee
- 1992 University of Iowa Hospitals, Eye Institute, Ancillary Services Design Team
- 1993 American Academy of Ophthalmology: Diabetes 2000 - State of Iowa Coordinator
- 1995 American Board of Ophthalmology, Oral Board Examiner; 1995-2014 Twenty-Year Service
Award
- 2010 American Academy of Ophthalmology Board of Trustees approves nomination to serve on
Academy Congressional Advocacy Committee starting January 1, 2010 for one-year term,
subsequently renewed annually, maximum of five years

- 2012 Colorado Medical Society, Council on Legislation, representing Denver Medical Society, actively serving
- 2014 American Academy of Ophthalmology Board of Trustees approves nomination to serve on Council, starting January 1, 2014, representing the Colorado Society of Eye Physicians and Surgeons
- 2014 Colorado Health Care Policy & Finance (Colorado Medicaid) Specialty Physician's Workgroup meeting, Denver, Colorado, first meeting at invitation of Judy Zerzan, MD, May 13, 2014
- 2014 U. S. Retina, Board of Directors
- 2014 Denver Medical Society, Board of Directors
- 2015 Colorado Medical Society's Task Force on Health Care Costs and Quality; 25 physicians appointed to engage with the State of Colorado's Commission on Affordable Health Care

XIII. Honors and Awards

- 2014 American Academy of Ophthalmology, Secretariat Award, from the Secretary for Federal Affairs
- 2013 American Academy of Ophthalmology, President's Award, Leadership Development Program Graduate
- 2013 American Academy of Ophthalmology, "I Am An Advocate" campaign rollout, 1 of 17 ophthalmologists nationally featured as exemplars of advocacy
- 2008 Rocky Mountain Lions Eye Institute, University of Colorado Health Sciences Center, Department of Ophthalmology, Volunteer Faculty Teaching Award. Awarded annually by graduating senior residents to one of 70 faculty
- 2008 Visionary Council Member, Certificate of Appreciation, Foundation Fighting Blindness
- 1996 American Academy of Ophthalmology Honor Award
- 1991 Charles D. Phelps Research Award
- 1986 Clinical Excellence Award, University of Illinois Eye and Ear Infirmary
- 1985 C.A.R.E. Award, University of Illinois Hospital

XIV. Bibliography

A. Papers published or in press:

1. Hayreh SS, Klugman MR, Podhajsky P, Berl M, Kimura AE, Kolder HE, Electroretinography in central retinal vein occlusion. [abstract]. Invest Ophthalmol Vis Sci 1988;29(suppl):67.
2. Fiscella R, Payman GA, Kimura AE, Small G. Intravitreal toxicity of cotrimoxazole. Ophthalmic Surg 1998;19:44-6.

3. Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. *Arch Ophthalmol* 1989;107(10):1445-52.
4. Folk JC, Weingeist TA, Coonan P, Blodi CF, Folberg R, Kimura AE. The treatment of serous macular detachment secondary to choroidal melanomas and nevi. *Ophthalmology* 1989;96(4):547-51.
5. Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from nonischemic central retinal vein occlusion during the early acute phase. *Graefes Arch Clin Exp Ophthalmol* 1990;228(3):201-17.
6. Blodi CF, Sobol WM, Kimura AE. Inverse retinitis pigmentosa as a distinct clinical entity. [abstract]. *Invest Ophthalmol Vis Sci* 1990;31(suppl):425.
7. Kimura AE, Folk JC, Bennett SR, Stone EM, Raphtis EM. Retinal function in ADNIV: electrophysiology. [abstract]. *Invest Ophthalmol Vis Sci* 1990;31(suppl): 497.
8. Mansour A, Blodi CF, Yannis RA, Kimura AE. Intraocular lens placement behind the posterior capsule. *Ophthalmic surg* 1990;21(3):211-2.
9. Bennett SR, Folk JC, Kimura AE, Russell SR, Stone EM, Raphtis EM. Autosomal dominant neovascular inflammatory vitreoretinopathy. *Ophthalmology* 1990;97(9):1125-36.
10. Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM. Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. *Am J Hum Genet* 1991;49(4):699-706.
11. Godley BF, Folk JC, Kimura AE. Factors predictive of visual outcome in age-related macular degeneration and subfoveal choroidal neovascular membranes. [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):711.
12. Stone EM, Khadivi P, Kimura AE, Sheffield VC. A rapid denaturing gradient gel method of screening for rhodopsin gene mutations in patients with retinitis pigmentosa [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):891.
13. Schultz PN, Sobol WM, Kimura AE. Nonrecordable scotopic electroretinogram in female carriers of a pedigree of choroideremia. [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):902.
14. Johnson CP, Kimura AE, Wells KK, Saunders RS, Chen-Wen B, Vigliotti AP, Gingrich RD, Trigg ME. Ophthalmic complications of bone marrow transplantation. [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):1222.
15. Kimura AE, Follmer B, McAllister D, Hayreh SS. Electroretinography after acute central retinal vein occlusion. [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):1228.
16. Joos K, Kimura AE, Follmer B, Chemtob S. Effect of ibuprofen upon the electroretinogram following asphyxia in the newborn pig. [abstract]. *Invest Ophthalmol Vis Sci* 1991;32(suppl):1297.
17. Sobol WM, Kimura AE, Kardon RH, Thompson HS. Pupillary constriction to darkness in a patient with blue-cone monochromatism. *J Clin Neuro Ophthalmol* 1991;11(1):53-4.
18. Stone EM, Kimura AE, Nichols BE, Khadivi P, Fishman GA, Sheffield VC. Regional distribution of retinal degeneration in patients with the proline to histidine mutation in codon 23 of the rhodopsin gene. *Ophthalmology* 1991;98(12):1806-13.
19. Kimura AE. Contact and Noncontact Lenses in Photocoagulation Therapy. In: Weingeist TA, Sneed SR, eds. *Laser Surgery in Ophthalmology: Practical Applications*. Norwalk, CT; Appleton & Lange, 1992:7-14.
20. Fishman GA, Stone EM, Sheffield VC, Gilbert LD, Kimura AE. Ocular findings associated with rhodopsin gene codon 17 and codon 182 transition mutations in dominant retinitis pigmentosa. *Arch Ophthalmol* 1992;110(1):54-62.
21. Brown DM, Nichols BE, Weingeist TA, Sheffield VC, Kimura AE, Stone EM. Procollagen-II gene mutation in Stickler syndrome. *Arch Ophthalmol* 1992;110(1):1589-93.

22. Stone EM, Kimura AE, Folk JC, Bennett SR, Nichols BEE, Streb LM, Sheffield VC. Genetic linkage of autosomal dominant neovascular inflammatory vitreoretinopathy to chromosome 11q13. *Hum Mol Genet* 1992;1(9):685-9.
23. Ginsburg RN, Miller-Meeks MJ, Kelly M, Kimura AE. Fluorescein concentrations in human breast milk. [abstract]. *Invest Ophthalmol Vis Sci* 1992;33(suppl):728.
24. Bordewick D, Parys-vanGinderdeuren R, Barna T, Kimura A, Chemtob S. Free radicals (FR) arise from and activate the cyclooxygenase (COX) pathway, which contributes to post-asphyxic (AX) changes in retinal and choroidal blood flow (RBF, CHFB) in the newborn pig. [abstract]. *Invest Ophthalmol Vis Sci* 1992;33(suppl):813.
25. Lehmer JM, Heckenlively JR, Stone EM, Kimura AE, Blanton SH, Daiger SP. Clinical characterizations of chromosome 8 autosomal dominant retinitis pigmentosa (UCLA-RP01) [abstract]. *Invest Ophthalmol Vis Sci* 1992;33(suppl):1396.
26. Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC. Genetic linkage of vitelliform macular degeneration (Best's Disease) to Chromosome-11q13. *Nat Genet* 1992;1(4):246-50.
27. Brown DM, Kimura AE, Ossoinig KC, Weiner GH. Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid. *Ophthalmology* 1992;99(9):1463-7.
28. Fine SL, Wood WJ, Isernhagen RD, Singerman LJ, Bressler NM, Folk JC, Kimura AE, Fish GE, Maguire MG, Alexander J. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: Results of a pilot randomized clinical trial [letter]. *Arch Ophthalmol* 1993;111(1):19-20.
29. Nichols BE, Drack AV, Vandenburg K, Kimura AE, Sheffield VC, Stone EM. A 2 base pair deletion in the RDS Gene Associated with Butterfly-Shaped pigment dystrophy of the fovea. [Published erratum appears in *Hum Mol Genet* 1993;2(8):1347]. *Hum Mol Genet* 1993;2(5):601-3.
30. Drack AV, Kimura AE, Keech RV, Stone EM. Clinical characterization and molecular genetic studies of autosomal recessive congenital stationary night blindness with myopia [abstract]. *Invest Ophthalmol Vis Sci* 1993;34(4):1148 (abstract 2189).
31. Nichols BE, Kimura AE, Streb LM, Sheffield VC, Stone EM. Mutations in the RDS gene are associated with butterfly-shaped pigment dystrophy of the fovea [abstract]. *Invest Ophthalmol Vis Sci* 1993;34(4):1149 (abstract 2191)
32. Stone EM, Vandenburg K, Kimura AE, Lam BL, Fishman GA, Heckenlively JR, Castillo TA, Sheffield VC. Novel mutations in the peripherin (RDS) and rhodopsin genes associated with autosomal dominant retinitis pigmentosa (ADRP) [abstract]. *Invest Ophthalmol Vis Sci* 1993;34(4):1149 (abstract 2196).
33. Bordewick D, Joos K, Follmer B, Zimmerman B, Barns T, Kimura A. Effect of light on the electroretinogram in newborn pigs [abstract]. *Invest Ophthalmol Vix Sci* 1993;34(4):1435 (abstract 3629).
34. Nichols BE, Sheffield VC, Vandenburg K. Drack AV, Kimura AE, Stone EM. Butterfly-Shaped Pigment Dystrophy of the Fovea Caused by a Point Mutation in Codon-167 of the RDS Gene. *Nat Genet* 1993;3(3):202-7.
35. Stone EM, Nichols BE, Kimura AE, Weingeist TA, Drack A, Sheffield VC. Clinical features of a Stargardt-like dominant progressive macular dystrophy with genetic linkage to chromosome 6q. *Arch Ophthalmol* 1994;112(6):765-72.
36. Joos KM, Kimura AE, Vandenburg K, Bartley JA, Stone EM. Ocular findings associated with a single base pair mutation in the Norrie Disease gene. *Arch Ophthalmol* 1994; 112(12):1574-9.
37. Follmer BA, Smith SC, Kimura AE. Electrophysiology testing and the ophthalmic registered nurse. *Insight* 1994;19(4):12-8.
38. Kemp CM, Jacobson SG, Cideciyan AV, Kimura AE, Sheffield VC, Stone EM. RDS gene mutations causing either macular degeneration or retinitis pigmentosa lead to similar abnormalities of dark adaptation [abstract]. *Invest Ophthalmol Vis Sci* 1994;35(4):1478 (abstract 1041).

39. Ross RD, Gupta S, Feist RM, Kimura AE. Cystoid macular edema following pneumatic retinopexy [abstract]. *Invest Ophthalmol Vis Sci* 1994;35(4):1538 (abstract 1326).
40. Brown DM, Vandenburg K, Nichols BE, Kimura AE, Weingeist TA, Sheffield VC, Stone EM. Incidence of frameshift mutations in the procollagen II gene in Stickler syndrome and identification of four new mutations [abstract]. *Invest Ophthalmol Vis Sci* 1994;35(4):1717 (abstract 2159)
41. Stone EM, Nichols BE, Kimura AE, Weingeist TA, Drack AV, Sheffield VC. Genetic linkage of a Stargardt-like dominant progressive macular dystrophy to Chromosome 6 [abstract]. *Invest Ophthalmol Vis Sci* 1994;35(4):1717 (abstract 2160).
42. Reddy CV, Gupta S, Folk JC, Walker J, Kimura AE. Acute enlargement of the blind spot in multifocal choroiditis and punctate inner choroidopathy [abstract]. *Invest Ophthalmol Vis Sci* 1994;35(4):2104 (abstract 3933).
43. Kemp CM, Jacobson SG, Cideciyan AV, Kimura AE, Sheffield VC, Stone EM. RDS gene mutations causing retinitis pigmentosa or macular degeneration lead to the same abnormality in photoreceptor function. *Invest Ophthalmol Vis Sci* 1994;35(8):3154-62.
44. Reddy CV, Brown JJ, Folk JC, Gupta S, Kimura AE, Walker JD. Enlargement of the blind spot in Multiple Evanescent White Dot Syndrome and multifocal choroiditis [abstract]. *Ophthalmology* 1994;101(9A):95.
45. Brown DM, Kimura AE, Weingeist TA, Stone EM. Erosive vitreoretinopathy: a new clinical entity. *Ophthalmology* 1994;101(4):694-704.
46. Kimura AE, Reddy CV, Folk JC, Farmer SG. Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator [letter]. *Retina* 1994;14(1):83-4.
47. Kimura AE, Drack AV, Stone EM. Retinitis Pigmentosa and Associated Disorders. In: Wright KW, ed. *Pediatric Ophthalmology and Strabismus*. St. Louis: Mosby, 1995;449-66.
48. Brown DM, Graemiger RA, Hergersberg M, Schinzel A, Messmer EP, Niemeyer G, Schneeberger SA, Streb LM, Taylor CM, Kimura AE, Weingeist TA, Sheffield C, Stone EM. Genetic linkage of Wagner disease and erosive vitreoretinopathy to chromosome 5q13-14. *Arch Ophthalmol* 1995;113(5):671-5.
49. Brown DM, Vandenburg K, Kimura AE, Weingeist TA, Sheffield VC, Stone EM. Novel frameshift mutations in the procollagen 2 gene (COL2A1) associated with Stickler syndrome (hereditary arthro-ophthalmopathy). *Hum Mol Genet* 1995;4(1):141-2.
50. Ross RD, Boone DE, Kimura AE. Hydroxychloroquine toxicity: the electroretinogram (ERG) findings in a patient with preexisting macular disease [abstract 795]. *Invest Ophthalmol Vis Sci* 1995;36(4):S163.
51. Boone DE, Boldt HC, Ross RD, Folk JC, Sanon A, Folberg R, Kimura AE. Intravitreal tissue plasminogen activator (tPA) in the treatment of subretinal hemorrhage [abstract 3432]. *Invest Ophthalmol Vis Sci* 1995;36(4):S742.
52. Brown J, Weleber RG, Kimura AE, Vandenburg K, Sheffield VC, Stone EM. Three families affected with a rapidly progressive severe form of autosomal dominant retinitis pigmentosa associated with mutations in codon 347 of the rhodopsin gene (pro-347-ala and pro-347-gln) [abstract 3814]. *Invest Ophthalmol Vis Sci* 1995;36(4):S825.
53. Brown J, Kimura AE, Gorin MB. Clinical Findings and Longitudinal Follow-Up of an X-Linked Progressive Cone Dystrophy Pedigree [abstract poster]. *Ophthalmology* 1995;102(9A):172.
54. Sternberg P, Brown JM, Curtis L, Fremstad A, Gibbs D, Swords R, Waldron RG, Bressler NM, Belt J, Bressler SB, Muth T, Elman MJ, George T, Haller JA, Herring M, Orr PR, Schachat AP, Sotirakos P, Starr J, Singerman LJ, Brown P, Coreno K, Delisio M, Novak M, Pinter AS, Folk JC, Kimura AE, et al. Occult choroidal neovascularization: influence on visual outcome in patients with age-related macular degeneration. *Arch Ophthalmol* 1996;114(4):400-12.

55. Wilkinson CP, Hawkins BS, Javornik NB, Newhouse MM, Keller JA, Bressler NM, Bressler SB, Burgess DB, Fine S, Hiner CJ, Maguire MG, Orth DH. Macular Photocoagulation Study Group. Folk JC, Kimura AE. Five-Year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1996;114(6):677-88.
56. Reddy CV, Brown J, Folk JC, Kimura AE, Gupta S, Walker J. Enlarged blind spots in chorioretinal inflammatory disorders. *Ophthalmology* 1996;103(4):606-17.
57. Brown J, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. *Ophthalmology* 1996;103(7):1100-5.
58. Boone DE, Boldt HC, Ross RD, Folk JC, Kimura AE. The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model. *Retina* 1996;16(6):518-24.
59. Mizener JB, Kimura AE, Adamus G, Thirkill CE, Goeken JA, Kardon RH. Autoimmune retinopathy in the absence of cancer. *Am J Ophthalmol* 1997;123(5):607-18.
60. Guyer DR, Adamis PA, Bird A, Brancato R, Coscas G, Gragoudas E, Yannuzzi LA, O'Shaughnessy D, Slakter JS, Miller JW, Soubrane G, Buyse M, Melis C, DeRosa JT, Baes P, Bressler N, Bressler S, Alexander J, Cooper R, Javornik N, Orlock D, Hanutsaha P, Chang A, Mott D, Betts F. The Pharmacological Therapy for Macular Degeneration Study Group. Folk J, Boldt HC, Kimura AE, Griffin M. Interferon Alfa-2A is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmology* 1997;115(7):865-72.
61. Polk TD, Kimura AE, Park D. Subretinal fluid associated with membranoproliferative glomerulonephritis type 2. *Arch Ophthalmol* 1997;115(7):927-8.
62. Seymour AB, Dash-Modi A, O'Connell JR, Shaffer-Gordon M, Mah TS, Stefko ST, Nagaraja R, Brown J, Kimura AE, Ferrell RE, Gorin MB. Linkage analysis of X-linked Cone-Rod Dystrophy: Localization to Xp11.4 and Definition of a Locus Distinct from RP2 and RP3. *Am J Hum Genet* 1998;62(1):122-9.
63. Hayreh SS, Zimmerman BZ, Kimura AE, Sanon A. Central retinal artery occlusion. Retinal survival time. *Experimental Eye Research* 78; (2004) 723-736.
64. Kudchadkar R, Gonzalez R, Robinson W, Becker M, Treichel K, Kimura AE, Lewis K, "The Absent-Minded Professor: An Unusual Complication of Melanoma," *Oncology*, Volume 22, Number 14, December 2008, pp. 1609-1614
65. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N, "Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections," *Ophthalmic Surgery, Lasers & Imaging*, Volume 40, Number 3, May/June 2009, pp 293-295
66. Good, Travis J; Kimura AE; Mandava, Naresh, et al. Sustained Elevation of Intraocular Pressure After Intravitreal Injections of Anti-VEGF Agents, *British Journal of Ophthalmology*, Published online, August 11, 2010; <http://bj.o.bmj.com/content/early/2010/08/11/bjo.2010.180729.full.html>;

B. Books and/or chapters:

1. Kimura AE: Chapter 2 - Contact and noncontact lenses in photocoagulation therapy. In Laser Surgery in Ophthalmology Practical Applications Eds. Thomas A. Weingeist, M.D., Scott R. Sneed, M.D. Appleton and Lange, Norwalk, Connecticut. pp.7-14. 1992.
2. Kimura AE, Drack AV, Stone EM: Retinitis pigmentosa and associated disorders in Pediatric Ophthalmology. Eds. K. Wright, F. Ellis Mets, M. DelMonte, E. Buckley, E. M. Stone. St. Louis, Mosby, 1995.
3. Kimura AE: Section 8. Hereditary Vitreoretinopathies. In Myron Yanoff and Jay S. Duker, editors, Ophthalmology. London: Mosby 1998. pp15.1-15.6.

4. Kimura AE: VII: Subretinal Surgery Techniques, Chapter 32: Surgical Removal of Subretinal Hemorrhage, pp. 357-363. In Vitreoretinal Surgical Techniques. Eds. GA Peyman, SA Meffert, MD Conway and F Chou. London, Martin Dunts, Ltd 2001.
5. Drack AV and Kimura AE: Section Seven: Pediatric Retinal Disease, Chapter 31: Retinitis Pigmentosa and Associated Disorders, pp. 539-555. Eds. KW Wright and PH Spiegel. New York, Springer-Verlag, 2002.
6. Kimura AE: Part 8: Retina and Vitreous, Section 4: Dystrophies, Chapter 112: Hereditary Vitreoretinopathies, pp. 843-848. Ophthalmology, Second Edition. Eds. M Yanoff and JS Duker. Mosby, 2004.
7. Kimura AE: VII: Subretinal Surgery Techniques, Chapter 36: Surgical Removal of Subretinal Hemorrhage, pp. 370-375. In Vitreoretinal Surgical Techniques, Second Edition. Eds. GA Peyman, SA Meffert, MD Conway. London, Informa UK Ltd 2007.
8. Kimura AE: Chapter 6.14: Hereditary Vitreoretinopathies. In Ophthalmology, Third Edition. Eds. M Yanoff and JS Duker, Mosby (2008).